Nanomedicine: Towards development of patient-friendly drug-delivery systems for oncological applications

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1043-1060

  Ranganathan, Ramya ^a   Madanmohan, Shruthilaya ^a   Kesavan, Akila ^a   Baskar, Ganga ^a   Krishnamoorthy, Yoganathan Ramia ^b   Santosham, Roy ^a   Ponraju, D ^c   Rayala, Suresh Kumar ^b   Venkatraman, Ganesh ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^c INDIRA GANDHI CENTRE FOR ATOMIC RESEARCH   (India)

Author keywords

Cancer; Drug delivery systems; Nanomedicine; Patient friendly

Indexed keywords

APOLIPOPROTEIN LABELED NANOPARTICLE; APTAMER LABELED NANOPARTICLE; CISPLATIN; COPOLYMER; CURCUMIN; DOXORUBICIN; FOLATE LINKED NANOPARTICLE; HER2 ANTIBODY LABELED NANOPARTICLE; LIPOSOME; MAGNETIC NANOPARTICLE; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; PEPTIDE LABELED NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RESEARCH; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; HEATING; HUMAN; HYPERTHERMIC THERAPY; LUNG CANCER; LUNG CARCINOMA; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OVARY CANCER; PROSTATE CANCER; STOMACH CANCER; ANIMAL; METHODOLOGY; ONCOLOGY; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MEDICAL ONCOLOGY; NANOMEDICINE; NEOPLASMS;

EID: 84862325100     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S25182     Document Type: Article

References (75)

1. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008;13:248-260.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70.
3. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-1626.
4. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523-580.
5. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297-315.
6. McNeil SE. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:264-271.
7. Burger KN, Staffhorst RW, de Vijlder HC, et al. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med. 2002;8:81-84.
8. Yuba E, Harada A, Sakanishi Y, Kono K. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes. J Control Release. 2011;149:72-80.
9. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15:1973-1980.
10. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond). 2008;3:761-776.
11. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm. 2009;366(1-2):201-210.
12. Strijkers GJ, Kluza E, Van Tilborg GA, et al. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis. 2010;13:161-173.
13. Singh SV, Hu X, Srivastava SK, et al. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis. 1998;19:1357-1360.
14. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005;280: 20059-20068.
15. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895-2900.
16. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol. 2008;32:1119-1123.
17. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104:1322-1331.
18. Han HD, Lee A, Hwang T, et al. Enhanced circulation time and antitumor activity of doxorubicin by comb like polymer-incorporated liposomes. J Control Release. 2007;120:161-168.
19. Laverman P, Brouwers AH, Dams ET, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther. 2000;293:996-1001.
20. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298:607-612.
21. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349-355.
22. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010;27:2569-2589.
23. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003;100:6039-6044.
24. Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm. 2009;6:468-479.
25. Vauthier C, Labarre D, Ponchel G. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target. 2007;15:641-663.
26. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicinloaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14: 97-105.
27. Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Influence of surfactants, polymer and doxorubicin loading on the antitumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul. 2006;23:582-592.
28. Brigger I, Morizet J, Aubert G, et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther. 2002;303:928-936.
29. Brigger I, Morizet J, Laudani L, et al. Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release. 2004;100:29-40.
30. Duan J, Zhang Y, Han S, et al. Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2010;400:211-220.
31. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm. 2010;7:815-825.
32. Brigger I, Chaminade P, Marsaud V, et al. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int J Pharm. 2001;214:37-42.
33. Stella B, Arpicco S, Rocco F, et al. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm. 2007;344(1-2):71-77.
34. Toub N, Bertrand JR, Tamaddon A, et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res. 2006;23(5):892-900.
35. Yousefi A, Esmaeili F, Rshimian S, Atyabi F, Dinarvand R. Preparation and in vitro evaluation of a pegylated nano-liposomal formulation containing docetaxel. Sci Pharm. 2009;77:453-464.
36. Sharma R, Yasir M, Bhaskar S, Asif M. Formulation and evaluation of paclitaxel loaded PSA-PEG nanoparticle. J App Pharm Sci. 2011;1: 96-98.
37. Nobs L, Buchegger F, Gurny R, Allmann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem. 2006;17:139-145.
38. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8:1172-1181.
39. Sun B, Ranganathan B, Feng SS. Multifunctional poly(D, L-lactide-coglycolide)/ montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008:29475-29486.
40. Day ES, Bickford LR, Slater JH, Riggall NS, Drezek RA, West JL. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int J Nanomedicine. 2010;5:445-454.
41. Shahzad MM, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011;13:309-319.
42. Wu P, He X, Wang K, et al. Imaging breast cancer cells and tissues using peptide-labeled fluorescent silica nanoparticles. J Nanosci Nanotechnol. 2008;8:2483-2487.
43. Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010;16: 3910-3922.
44. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103:6315-6320.
45. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007;26:141-152.
46. Kamen BA, Smith AK. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004;56:1085-1097.
47. Antony AC. The biological chemistry of folate receptors. Blood. 1992;79:2807-2820.
48. Mathias CJ, Hubers D, Low PS, Green MA. Synthesis of [(99 m) Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem. 2000;11:253-257.
49. Ulbrich K, Michaelis M, Rothweiler F, et al. Interaction of folateconjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm. 2011;406:128-134.
50. Rossin R, Pan D, Qi K, et al. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med. 2005;46: 1210-1218.
51. Yang SJ, Lin FH, Tsai HM, et al. Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. Biomaterials. 2011;32:2174-2182.
52. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposomeentrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233: 134-144.
53. Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res. 2003;20:417-422.
54. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol. 2004;11:996-1004.
55. Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther. 2005:1423-1429.
56. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004;58:1215-1227.
57. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-2407.
58. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta. 2008:854-863.
59. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732-6740.
60. Pun SH, Tack F, Bellocq NC, et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther. 2004;3:641-650.
61. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther. 2006;5:818-824.
62. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
63. Izumi Y, Xu L, Tomaso E, Fukumura D, Jain RK. Tumor biology: Herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279-280.
64. Gazeau F, Lévy M, Wilhelm C. Optimizing magnetic nanoparticle design for nanothermotherapy. Nanomed. 2008;3:831-844.
65. Krishnan S, Diagaradjane P, Cho S. Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. Int J Hyperthermia. 2011;26:775-789.
66. DeNardo GL, DeNardo SJ. Update: turning the heat on cancer. Cancer Biother Radiopharm. 2008;23:671-680.
67. Santosham R, Dev B, Priyadarshini P, et al. How I do it: Radiofrequency ablation. Indian J Radiol Imaging. 2008;18:166-170.
68. Merkle EM, Goldberg SN, Boll DT, et al. Effects of superparamagnetic iron oxide on radiofrequency-induced temperature distribution: in vitro measurements in polyacrylamide phantoms and in vivo results in a rabbit liver model. Radiology. 1999;212:459-466.
69. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine. 2008;3:169-180.
70. Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. Int J Hyperthermia. 2008;24:467-474.
71. Roca AG, Costo R, Rebolledo AF, et al. Progress in the preparation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys. 2009;42:224002-224012.
72. Ivkov R, DeNardo SJ, Daum W, et al. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res. 2005;11:7093-7103.
73. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103:317-324.
74. Occhipinti E, Verderio P, Natalello A, et al. Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles. Nanoscale. 2011;3:387-390.
75. Natarajan A, Xiong CY, Gruettner C, DeNardo GL, DeNardo SJ. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm. 2008;23:82-91.